DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company's Phase 3 VITESSE clinical trial of the VIASKIN® Peanut patch in peanut allergic children aged 4-7 years. With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year.

GlobeNewsWire • Nov 12, 2025

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts.

GlobeNewsWire • Nov 4, 2025

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr.

GlobeNewsWire • Nov 3, 2025

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

Here is how DBV Technologies S.A. (DBVT) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Zacks Investment Research • Oct 31, 2025

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled “Harnessing Immune Plasticity to Alter the Path of Food Allergy”.

GlobeNewsWire • Oct 30, 2025

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025.

GlobeNewsWire • Oct 30, 2025

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $30 million, before deducting sales agent commissions and offering expenses payable by the Company, to Artisan Partners Limited Partnership (“Artisan”) through Citizens Capital Markets, acting as sales agent. Each ADS represents the right to receive five Ordinary Shares of the Company.

GlobeNewsWire • Oct 29, 2025

Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength?

DBV Technologies (DBVT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Oct 17, 2025

New Strong Sell Stocks for September 23rd

ATS, ASRT and DBVT have been added to the Zacks Rank #5 (Strong Sell) List on September 23, 2025.

Zacks Investment Research • Sep 23, 2025

DBV Technologies Announces Resignation of Board Member

Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV's management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Rosen, Chairman of the Board.

GlobeNewsWire • Sep 18, 2025